(S)-(+)-Ibuprofen - CAS 51146-56-6
Catalog number:
51146-56-6
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C13H18O2
Molecular Weight:
206.28
COA:
Inquire
Targets:
Cox-2 | COX
Description:
Be capable of inhibiting cyclooxygenase (COX) at clinically relevant concentrations; As an enantiomer of (R)-(-)-Ibuprofen, it more potently inhibits COX activity; A non-steroidal anti-inflammatory drug
Publictions citing BOC Sciences Products
  • >> More
Brife Description:
Be capable of inhibiting cyclooxygenase (COX) at clinically relevant concentrations; As an enantiomer of (R)-(-)-Ibuprofen, it more potently inhibits COX activity; A non-steroidal anti-inflammatory drug
Appearance:
White to Off-White Solid
Synonyms:
(S)-Ibuprofen
Solubility:
100mMin DMSO;100mM in ethanol; dichloromethane, ethyl acetate, and methanol;
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
MSDS:
Inquire
Quality Standard:
In-house
Quantity:
Grams-Kilos
Melting Point:
45-47°C
InChIKey:
HEFNNWSXXWATRW-JTQLQIEISA-N
InChI:
1S/C13H18O2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15/h4-7,9-10H,8H2,1-3H3,(H,14,15)/t10-/m0/s1
Canonical SMILES:
CC(C)CC1=CC=C(C=C1)C(C)C(=O)O
1.Influence of temperature on toxicity of single pharmaceuticals and mixtures, in the crustacean A. desmarestii.
Nieto E1, Hampel M2, González-Ortegón E3, Drake P4, Blasco J4. J Hazard Mater. 2016 Mar 24;313:159-169. doi: 10.1016/j.jhazmat.2016.03.061. [Epub ahead of print]
Lethal and sublethal responses of the shrimp Atyaephyra desmarestii exposed to three pharmaceutical compounds, Diclofenac (DF), Ibuprofen (IB) and Carbamazepine (CBZ), individually and in mixtures, were evaluated under two temperature scenarios. LC50 (96h) values were obtained individually at 20° and 25°C. At 25°C, mortality in binary and ternary mixtures is higher than at 20°C. The toxicity of the mixtures was predicted on the basis of individual mortality data using two toxicity models: Concentration addition (CA) and Independent action (IA). Our results showed that neither CA nor IA unequivocally predicted the observed toxicity of binary and ternary mixtures. For sublethal toxicity, selected endpoints were: ingestion rate, osmoregulatory capacity and respiration rate. Regarding osmoregulatory capacity, no significant differences were found. The highest ingestion rates were recorded in organisms exposed at 25°C, irrespective of the compound, after 30 and 60min of exposure.
2.Active removal of ibuprofen by Money plant enhanced by ferrous ions.
Chehrenegar B1, Hu J2, Ong SL1. Chemosphere. 2016 Feb;144:91-6. doi: 10.1016/j.chemosphere.2015.08.060. Epub 2015 Sep 5.
In this study, the removal of ibuprofen (IBP), a pharmaceutical compound, from aqueous media by Money plant (Epipremnum aureum) was investigated. The effect of ferrous iron (Fe(2+)) on enhancing the IBP removal rate was also analyzed. The first-order removal rate constants showed higher values for lower IBP initial concentrations in the range of 0.20-0.28 d(-1) for an initial concentration of 125 μg L(-1) to 0.03-0.13 d(-1) for an initial concentration of 1000 μg L(-1). Introducing ferrous iron to the aqueous media enhanced the first-order removal rate constant up to 6.5 times in a 3 d time period. Along with the removal of IBP from the media, the endogenous concentration of H2O2 also decreased presumably by the production of hydroxyl radical (·OH). Reduction in the endogenous H2O2 concentration was recorded to be 38% and 98% in the absence and presence of Fe(2+) respectively in the first day and the H2O2 level remained considerably low until day 7 which then gradually increased slightly.
3.Efficacy and safety of oral NSAIDs and analgesics in the management of osteoarthritis: Evidence from real-life setting trials and surveys.
Pelletier JP1, Martel-Pelletier J2, Rannou F3, Cooper C4. Semin Arthritis Rheum. 2016 Feb;45(4 Suppl):S22-7. doi: 10.1016/j.semarthrit.2015.11.009. Epub 2015 Dec 2.
Non-steroidal anti-inflammatory drugs (NSAIDs) are at the cornerstone of treatment for osteoarthritis (OA). In recent years, the widespread use of oral NSAIDs has been called into question due to the appearance of significant upper gastrointestinal (GI) complications and cardiovascular (CV) adverse events (AEs). However, NSAIDs are non-homogeneous, and there are noticeable differences between them in AE risk for GI and CV events. Nevertheless, if properly prescribed oral NSAIDs can provide an effective and safe treatment for OA in real-life situations. The identification of patients with significant CV and/or GI risk is critical, and the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) treatment algorithm provides guidance on appropriate treatments for OA patients with elevated risk. Among non-selective NSAIDs, ibuprofen and naproxen seem preferable to diclofenac, the latter being associated with higher CV risk.
4.Cysteine amide adduct formation from carboxylic acid drugs via UGT-mediated bioactivation in human liver microsomes.
Harada H, Toyoda Y, Endo T, Kobayashi M. Pharmazie. 2015 Oct;70(10):678-83.
Although chemical trapping has been widely used to evaluate cytochrome P450-mediated drug bioactivation, thus far, only a few in vitro-trapping studies have been performed on UDP-glucuronosyltransferase (UGT)-mediated drug bioactivation. In this study, we used cysteine (Cys) as trapping agent to gain new insights into the UGT-mediated bioactivation involving acyl glucuronides of carboxylic acid drugs. Diclofenac, ketoprofen and ibuprofen were incubated in human liver microsomes with UDPGA and Cys, followed by analysis using ultra-performance liquid chromatography-quadrupole time-of-flight mass spectrometry (UPLC-QTOF/MS). The N-acyl-Cys amide adduct of diclofenac was characterized by mass analysis and was detectable even in photodiode array analysis. Our data indicated that the formation of such adducts reflects the reactivity of the corresponding acyl glucuronides. In addition, it was suggested that the adduct formation requires an N-terminal Cys moiety with both a free amine and a free thiol group, from the results using various cysteine derivatives.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Cox-2 Products


N-(4-acetamidophenyl)-Indomethacin amide
(CAS: 261766-23-8)

An elective reversible inhibitors of COX-2

O-Acetyl Salicylhydroxamic Acid
(CAS: 199854-00-7)

An irreversible, non-selective inhibitor of COX-1 and COX-2

CAS 31842-01-0 Indoprofen

Indoprofen
(CAS: 31842-01-0)

Indoprofen, a non-steroidal anti-inflammatory drug, is a cyclooxygenase inhibitor and used for the treatment of pain and inflammation and spinal muscular atroph...

CAS 36322-90-4 Piroxicam

Piroxicam
(CAS: 36322-90-4)

Piroxicam is a non-selective COX inhibitor with an IC50 of 6 mM.

CAS 53716-49-7 Carprofen

Carprofen
(CAS: 53716-49-7)

A COX-2 inhibitor; A non-steroidal anti-inflammatory drug

CAS 181695-72-7 Valdecoxib

Valdecoxib
(CAS: 181695-72-7)

A selective COX-2 inhibitor

CAS 123653-11-2 NS 398

NS 398
(CAS: 123653-11-2)

A selective COX-2 inhibitor

CAS 38194-50-2 Sulindac

Sulindac
(CAS: 38194-50-2)

Sulindac is a non-steroidal COX inhibitor, which potently inhibits prostaglandin synthesis, used in the treatment of acute or chronic inflammatory conditions.

CAS 70374-39-9 Lornoxicam

Lornoxicam
(CAS: 70374-39-9)

A non-steroidal COX-1/COX-2 inhibitor; A nonsteroidal anti-inflammatory drug

CAS 64490-92-2 Tolmetin sodium dihydrate

Tolmetin sodium dihydrate
(CAS: 64490-92-2)

Tolmetin sodium dihydrate is a non-steroidal anti-inflammatory agent for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis.

CAS 188817-13-2 SC-560

SC-560
(CAS: 188817-13-2)

SC-560 is an orally active and highly selective cyclooxygenase-1 (COX-1) inhibitor with IC50= 0.009 μM for COX-1, and 6.3 μM for COX-2. SC-560 also significantl...

CAS 180200-68-4 JTE522

JTE522
(CAS: 180200-68-4)

JTE522, a selective COX-2 inhibitor, can induce apoptosis and inhibit cell proliferation in human endometrial cancer cell line RL95-2 cells and to explore the m...

CAS 51803-78-2 Nimesulide

Nimesulide
(CAS: 51803-78-2)

A selective COX-2 inhibitor

CAS 88149-94-4 DuP-697

DuP-697
(CAS: 88149-94-4)

A selective COX-2 inhibitor

CAS 168433-84-9 SC58451

SC58451
(CAS: 168433-84-9)

SC58451 is a potent and selective Cox-2 (IC50= 1.1 nM) and was found to be orally active (EDs0 = 0.3 mpk) in the rat<br/>adjuvant-induced arthritis model with n...

CAS 162011-90-7 Rofecoxib

Rofecoxib
(CAS: 162011-90-7)

A COX-2 inhibitor( IC50s = 26 nM and > 50 µM in human osteosarcoma cells )

CAS 51146-56-6 (S)-(+)-Ibuprofen

(S)-(+)-Ibuprofen
(CAS: 51146-56-6)

Be capable of inhibiting cyclooxygenase (COX) at clinically relevant concentrations; As an enantiomer of (R)-(-)-Ibuprofen, it more potently inhibits COX activi...

N-(3-pyridyl)-Indomethacin amide
(CAS: 261766-29-4)

A potent and selective reversible inhibitor of COX-2

CAS 74103-06-3 Ketorolac

Ketorolac
(CAS: 74103-06-3)

Ketorolac, a non-selective COX inhibitor, is a non-steroidal anti-inflammatory drug. It shows inhibition of eicosanoid formation in HEL cells (COX-1) and LPS-st...

CAS 15307-79-6 Diclofenac Sodium

Diclofenac Sodium
(CAS: 15307-79-6)

A non-selective COX inhibitor with IC50 of 0.5 μg/ml and 0.5 μg/ml for COX-1 and -2 in intact cells, respectively

Chemical Structure

CAS 51146-56-6 (S)-(+)-Ibuprofen

Quick Inquiry

Verification code

Featured Items